Carolyn Hamby Shelton Buys 6,000 Shares of Nexalin Technology, Inc. (NASDAQ:NXL) Stock

Nexalin Technology, Inc. (NASDAQ:NXL) VP Carolyn Hamby Shelton acquired 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average cost of $2.20 per share, with a total value of $13,200.00. Following the acquisition, the vice president now owns 30,000 shares in the company, valued at $66,000. The trade was a 25.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nexalin Technology Trading Up 10.3 %

Shares of NXL opened at $2.15 on Friday. The company has a market cap of $28.60 million, a PE ratio of -3.36 and a beta of 4.33. The stock has a 50-day moving average price of $2.85 and a 200-day moving average price of $2.47. Nexalin Technology, Inc. has a 12-month low of $0.35 and a 12-month high of $4.49.

Nexalin Technology (NASDAQ:NXL) last released its earnings results on Friday, March 14th. The company reported ($0.28) earnings per share for the quarter. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%.

Analysts Set New Price Targets

Separately, Maxim Group reissued a “hold” rating on shares of Nexalin Technology in a report on Thursday, December 5th.

Institutional Trading of Nexalin Technology

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Nexalin Technology in the 4th quarter worth approximately $28,000. Northern Trust Corp bought a new stake in Nexalin Technology in the 4th quarter worth approximately $36,000. XTX Topco Ltd purchased a new position in Nexalin Technology in the 4th quarter worth approximately $46,000. Geode Capital Management LLC increased its stake in Nexalin Technology by 36.3% in the 4th quarter. Geode Capital Management LLC now owns 107,241 shares of the company’s stock worth $296,000 after purchasing an additional 28,544 shares during the period. Finally, Kingsview Wealth Management LLC purchased a new position in Nexalin Technology in the 4th quarter worth approximately $28,000. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.